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Each time I receive an issue of Virchows Archiv (The
European Journal of Pathology), I realise with a feeling of
pride that I am part of an incredible tradition in medical
publication: 165 years of continuous pathology publishing!
The journal was founded by our intellectual forebear
Rudolf Virchow as ‘Archiv für Pathologische Anatomie
und Physiologie und für Klinische Medicin’ in 1847. The
first change in name occurred in 1903 when, for the
171st volume, the name of the founder was added to the
name of the journal. Thus it became ‘Virchows Archiv
fuer Pathologische Anatomie und Physiologie und für
Klinische Medizin’. With foresight the editors of the
journal in 1968 decided to create two different sections
of the journal: volume 344 had part A dedicated to
‘Pathologische Anatomie und Histologie’ and part B
dedicated to ‘Zellpathologie’, later changed into ‘Pathological
Anatomy and Histology’ and ‘Cell Pathology’. These changes
anticipated the important impact that the development of
molecular biology would have on our understanding of the
mechanisms involved in disease and the implications of this
knowledge for the practice of diagnostic histo- and
cytopathology. The journal also started to accept papers
written in English, which in the second half of the
twentieth century had become the new ‘lingua franca’ of
science. Just a decade later, English became the sole
language for the journal, with another name change: the
German name versions disappeared. Again with fore-
sight, the designation ‘Molecular Pathology’ was added
to part B. In 1994, another decade later—we were now at
volume 424—the two sections were fused, underlining
the notion that cellular and molecular mechanisms of
disease are an intricate part of pathology, be it in
research or in diagnostic practice. The global orientation
of the journal was reflected in the subtitle ‘An Interna-
tional Journal of Pathology’. In 1999 the journal became
officially associated with the European Society of
Pathology and, with volume 454 in 2009, the journal
metamorphosed in appearance (some like the flashy
almost psychedelic colours, others do not) and again in
name: the subtitle became ‘The European Journal of
Pathology’.
I have accepted the invitation to take over as editor in
chief from January 2012. I stand in awe of those who have
brought the journal to where it is today. Great names from
the past such as Lubarsch, Hamperl, Uehlinger, Doerr,
Seifert and, in recent decades, Victor Gould, Sir Colin
Berry, Philipp Heitz, Manfred Dietel, Vincenso Eusebi,
Günter Klöppel, who ran the journal from 1994 to 2003,
Pierre Bedossa; the three latter names still being on the list
of managing editors. Last but not least, Heinz Höfler, the
outgoing editor in chief. We owe an immense, respectful
debt of gratitude to Heinz for the energy with which he has
handled the journal and his vision, whereby he has brought
the journal to its present position: at the forefront of
pathology publishing in an era of rapid change, in terms of
both the transformation in publishing and the molecular
revolution in biomedicine.
The fun part of taking on this responsibility is the
opportunity to reflect on the future and to endeavour to
maintain the journal in the mainstream of pathology
publishing in these very dynamic times. A group of
dedicated pathologists came together in the summer of
2011 to anticipate the future of pathology and the directions
the journal would need to take to remain in that
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mainstream. So what came out of this? What should the
identity of the journal be? Where do we want to go?
Quite a bit of time was spent on a discussion regarding
the mission statement: ‘To advance the scientific basis of
human pathology by the publication of high quality
research (including molecular and translational studies)
and thereby contribute to patient care.’ Publication should
be regarded in this context not as passive waiting for
submitted papers but actively encouraging new generations
of pathologists to engage in scientific observation and to
publish their data, as well as the active dissemination of
new findings in the electronic age. We also set out to define
the type of manuscript that would be characteristic of the
journal’s content. Evidence-based pathology was chosen
as the essential prerequisite: ‘Manuscripts of original
studies reinforcing the evidence base of modern diagnostic
pathology, using immunocytochemical, molecular and
ultrastructural techniques, will be welcomed. In addition,
papers on the critical evaluation of diagnostic criteria but
also broadsheets and guidelines with a solid evidence
base will be considered. Consideration will also be given
to reports of work in other fields relevant to the
understanding of human pathology as well as manuscripts
on the application of new methods and techniques in
pathology.’ Purely experimental pathology, as important as it
remains for understanding mechanisms of disease, will not be
one of the core interests of the journal. ‘Submission of purely
experimental articles is discouraged but manuscripts on
experimental work applicable to diagnostic pathology are
welcomed.’ In this era of personalised medicine, biomarker
studies will be of increasing importance and therefore
‘Biomarker studies are welcomed’when they follow stringent
methodological principles ‘but need to abide by strict rules
(e.g. REMARK—the NCI/EORTC reporting recommenda-
tions for tumour marker prognostic studies) of adequate
sample size and relevant marker choice. Single marker studies
on limited patient series without validated application will as a
rule, not be considered.’ This will include retrospective
histopathological analysis of tissue from prospective studies,
notably from tissue samples collected in the context of
clinical trials. Unique case studies can be exciting and
enlightening but ‘Case reports will only be considered
when they provide substantial new information with an
impact on understanding disease or diagnostic practice.’
So these will be the guiding principles for the future
development of the journal.
Obviously, what authors and editors want is only one
side of the coin. Readers should have an important voice in
determining the content of the journal and a readership
survey will be circulated shortly. When the message arrives
in your mailbox, please do not delete it right away but take
a few minutes to complete it; we need your input. To make
you aware of what the journal publishes an email alert with
a table of contents will be sent out to all subscribers and all
others who enlist for this service. To increase interest in
original papers published in the journal an annual Virchows
Archiv, prize will be awarded: a short list of outstanding
papers will be voted on by the editorial board and the prize
will be awarded at the annual European Congress of
Pathology. To attract more attention to good papers we
publish, there will be an effort to improve their titles and to
make the abstracts more informative. So do not be surprised
if the editorial office suggests a more declarative title for
your accepted paper. To lure potential authors to Virchows
Archiv, members of the editorial team will actively solicit
papers at European Congresses and European Society of
Pathology courses. As others have done (we do not pretend
to be totally original), we will publish an annual review
issue as of 2013. The topics of the annual review issues
will have a strong evidence-based pathology/guideline
orientation. There will be a few new ‘fun’ items; for
example, we will publish facsimiles of papers published
by our intellectual ancestors over the last 50–100 years.
We are seriously considering a ‘News and views’ section
at the beginning of the journal. The journal would like to
be informative to a broad readership and to keep that
readership abreast of what is new out there; this will be
the primary goal of this new section. Other ideas are to
increase the visibility of the journal through a Facebook
page and an item in Wikipedia. My grandchildren use
these social media and even I have realised their potential and
would like them to be able to appreciate what our discipline
is all about.
You might think ‘ambitions, ambitions, let us wait and
see what happens.’ You are right. Making plans is easy.
Getting to where we want to be will take a lot of energy. I
am fortunate not to have to do this all by myself. A skilled
and dedicated editorial team is there to actively contribute.
A partially renewed crew of editorial board members will
be challenged to participate in this adventure. An office and
a dedicated and experienced secretary (Dagmar Schmöe,
what would we be without her?) provide essential
infrastructural support. The Springer office is on board.
But we need you out there: the author to share new
knowledge through publishing in Virchows Archiv; the
reader to digest its content, apply it in practice and
comment or initiate new studies. For all of us this is
going to be a fascinating adventure.
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